个性化 mRNA 癌症疫苗的免疫原性和疗效。

IF 29.7 1区医学 Q1 ONCOLOGY

Cancer discovery Pub Date : 2024-11-01 DOI:10.1158/2159-8290.CD-24-1196

Pedro Berraondo, Raquel Cuesta, Miguel F Sanmamed, Ignacio Melero

{"title":"个性化 mRNA 癌症疫苗的免疫原性和疗效。","authors":"Pedro Berraondo, Raquel Cuesta, Miguel F Sanmamed, Ignacio Melero","doi":"10.1158/2159-8290.CD-24-1196","DOIUrl":null,"url":null,"abstract":"In this issue, Gainor and colleagues report on the immunogenicity of personalized neoantigen-encoding mRNA vaccines that elicit measurable polyfunctional CD8+ and CD4+ T-cell responses in patients whose tumors have been resected. Reactivity is substantiated to 20% to 30% of the predicted MHC-I and MHC-II epitopes in four patients with NSCLC postsurgically treated with the vaccine alone and in 12 patients with melanoma treated with their individualized vaccines plus pembrolizumab in the context of a phase 1 clinical trial (NCT03313778). See related article by Gainor et al., p. 2209.","PeriodicalId":9430,"journal":{"name":"Cancer discovery","volume":"14 11","pages":"2021-2024"},"PeriodicalIF":29.7000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Immunogenicity and Efficacy of Personalized Adjuvant mRNA Cancer Vaccines.\",\"authors\":\"Pedro Berraondo, Raquel Cuesta, Miguel F Sanmamed, Ignacio Melero\",\"doi\":\"10.1158/2159-8290.CD-24-1196\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In this issue, Gainor and colleagues report on the immunogenicity of personalized neoantigen-encoding mRNA vaccines that elicit measurable polyfunctional CD8+ and CD4+ T-cell responses in patients whose tumors have been resected. Reactivity is substantiated to 20% to 30% of the predicted MHC-I and MHC-II epitopes in four patients with NSCLC postsurgically treated with the vaccine alone and in 12 patients with melanoma treated with their individualized vaccines plus pembrolizumab in the context of a phase 1 clinical trial (NCT03313778). See related article by Gainor et al., p. 2209.\",\"PeriodicalId\":9430,\"journal\":{\"name\":\"Cancer discovery\",\"volume\":\"14 11\",\"pages\":\"2021-2024\"},\"PeriodicalIF\":29.7000,\"publicationDate\":\"2024-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer discovery\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1158/2159-8290.CD-24-1196\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer discovery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1158/2159-8290.CD-24-1196","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

在本期杂志中，Gainor及其同事报告了个性化新抗原编码mRNA疫苗的免疫原性，这种疫苗能在肿瘤已切除的患者中引起可测量的多功能CD8+和CD4+T细胞反应。在一项 1 期临床试验（NCT03313778）中，4 名 NSCLC 患者术后单独接种了疫苗，12 名黑色素瘤患者接种了他们的个性化疫苗和 pembrolizumab，证实了他们与 20% 至 30% 的预测 MHC-I 和 MHC-II 表位的反应。参见 Gainor 等人的相关文章，第 2209 页。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Immunogenicity and Efficacy of Personalized Adjuvant mRNA Cancer Vaccines.

In this issue, Gainor and colleagues report on the immunogenicity of personalized neoantigen-encoding mRNA vaccines that elicit measurable polyfunctional CD8+ and CD4+ T-cell responses in patients whose tumors have been resected. Reactivity is substantiated to 20% to 30% of the predicted MHC-I and MHC-II epitopes in four patients with NSCLC postsurgically treated with the vaccine alone and in 12 patients with melanoma treated with their individualized vaccines plus pembrolizumab in the context of a phase 1 clinical trial (NCT03313778). See related article by Gainor et al., p. 2209.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Cancer discovery ONCOLOGY-

CiteScore

22.90

自引率

1.40%

发文量

838

审稿时长

6-12 weeks

期刊介绍： Cancer Discovery publishes high-impact, peer-reviewed articles detailing significant advances in both research and clinical trials. Serving as a premier cancer information resource, the journal also features Review Articles, Perspectives, Commentaries, News stories, and Research Watch summaries to keep readers abreast of the latest findings in the field. Covering a wide range of topics, from laboratory research to clinical trials and epidemiologic studies, Cancer Discovery spans the entire spectrum of cancer research and medicine.